Loading insider details...
Beta
Latest Form 4 (Jun 22, 2026): Grant/Award of 20,275 ACRV shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 22, 2026 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 20,275 | n/a |
| Jun 5, 2026 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/Award | 42,000 | n/a |
| May 20, 2026 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 9,366 | n/a |
| Jun 17, 2025 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 20,275 | n/a |
| Jun 9, 2025 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/Award | 33,500 | n/a |
| Jun 24, 2024 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 20,275 | n/a |
| Jun 18, 2024 | Poseida Therapeutics, Inc. (PSTX) | Grant/Award | 19,650 | n/a |
| Jun 10, 2024 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/Award | 67,500 | n/a |
| Jan 23, 2024 | Mirati Therapeutics, Inc. (MRTX) | Disposition to Issuer | 123,389 | n/a |
| Jun 28, 2023 | Acrivon Therapeutics, Inc. (ACRV) | Grant/Award | 32,500 | n/a |